Efficacy and Safety of Metreleptin in Patients With Partial Lipodystrophy: Lessons From an Expanded Access Program

Journal of Diabetes & Metabolism
doi 10.4172/2155-6156.1000659
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

The Maraviroc Expanded Access Program — Safety and Efficacy Data From an Open-Label Study

HIV Clinical Trials
2015English

Psy11 - Real-World Experience of Generalized Lipodystrophy Patients Enrolled in the Metreleptin Early Access Program: Initial Results

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Clinical Effects of Long-Term Metreleptin Treatment in Patients With Lipodystrophy

Endocrine Practice
MedicineEndocrinologyMetabolismDiabetes
2011English

Efficacy and Safety of Defibrotide in a Subset Analysis of Late-Onset Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) Patients From an Ongoing, Expanded-Access Program

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Metreleptin in Lipodystrophy: A Profile of Its Use

Drugs and Therapy Perspectives
Pharmacology
2019English

EFFECTS: An Expanded Access Program of Everolimus for Patients With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex

BMC Neurology
MedicineNeurology
2016English

Metreleptin-Mediated Improvements in Insulin Sensitivity Are Independent of Food Intake in Humans With Lipodystrophy

Journal of Clinical Investigation
Medicine
2018English

1302pdifct-1502 CLINIVO: Real-Life Experience With Nivolumab in 600 Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): Efficacy and Safety of Nivolumab and Post-Nivolumab Treatment in the French Expanded Access Program (EAP)

Annals of Oncology
MedicineOncologyHematology
2017English

Acquired Partial Lipodystrophy

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy